View ValuationMentice 향후 성장Future 기준 점검 4/6Mentice (는) 각각 연간 109.4% 및 9.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 109.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.1% 로 예상됩니다.핵심 정보109.4%이익 성장률109.56%EPS 성장률Healthcare Services 이익 성장19.9%매출 성장률9.3%향후 자기자본이익률9.13%애널리스트 커버리지Low마지막 업데이트31 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jul 26New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€38.1m market cap, or US$43.3m).Reported Earnings • Jul 24Second quarter 2026 earnings released: kr0.03 loss per share (vs kr0.57 loss in 2Q 2025)Second quarter 2026 results: kr0.03 loss per share (improved from kr0.57 loss in 2Q 2025). Revenue: kr83.0m (up 31% from 2Q 2025). Net loss: kr880.0k (loss narrowed 95% from 2Q 2025). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings.공고 • Jul 23+ 1 more updateMentice AB (publ) to Report Fiscal Year 2026 Results on Apr 22, 2027Mentice AB (publ) announced that they will report fiscal year 2026 results on Apr 22, 2027공고 • Feb 27Mentice AB (publ) Announces Board ChangesMentice AB (publ) at its EGM held on February 26, 2026, announced that Göran Malmberg, previously CEO of the Company, was elected, for the period until the next annual shareholders’ meeting, as a new board member in the Company. Former board members David J. Ballard, Eola Änggård Runsten and Magnus Nilsson stepped down from the board. Göran Malmberg served as a board member in 2007 before assuming the role of CEO in January 2008, a position he held until December 31, 2024, when Frans Venker assumed the role as new CEO. Since 2025, Göran Malmberg serves as an advisor to the Company and its owners, and following the recent change of ownership, he now in addition assumes the role of board member.공고 • Feb 12Mentice AB (publ) to Report Fiscal Year 2025 Final Results on Apr 23, 2026Mentice AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 23, 2026공고 • Feb 05+ 3 more updatesMentice AB (publ) to Report Q1, 2026 Results on May 07, 2026Mentice AB (publ) announced that they will report Q1, 2026 results on May 07, 2026공고 • Oct 24Mentice AB (publ), Annual General Meeting, May 26, 2026Mentice AB (publ), Annual General Meeting, May 26, 2026. Location: gothenburg Sweden공고 • Jul 24Mentice AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 31.961063 million.Mentice AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 31.961063 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,556,885 Price\Range: SEK 12.5 Transaction Features: Rights Offering공고 • Jul 11Mentice AB (publ) Announces Consolidation of Physical Simulation Operations to Strengthen Long-Term Efficiency and Global Service DeliveryMentice AB (publ) announced the decision to consolidate its research and development (R&D) and manufacturing operations for its entire physical simulation portfolio to its new facility in Denver, Colorado, USA.공고 • Nov 29Mentice AB (publ) Announces the Appointment of Frans Venker as New Chief Executive Officer, Effective January 1, 2025Mentice AB (publ) announced the appointment of Frans Venker as its new Chief Executive Officer, effective January 1, 2025. Frans Venker succeeds Göran Malmberg, who has served the company for 17 years and will remain in an advisory role. Göran Malmberg’s retirement as CEO was previously announced in May 2024. With over 25 years of experience in the industry addressing the same or related medical needs and therapies as Mentice, Venker brings a wealth of expertise and a proven track record in driving innovation, operational excellence, and sustainable growth. Most recently, he led the Business Unit for Computed Tomography and Advanced Molecular Imaging at Philips based in the USA. Before this role, he was the Business Leader of image-guided Therapy for Philips North America and a member of the Philips North America Leadership Team and has served as Global Marketing Leader for Diagnostic X-Ray in Shanghai, China, in addition to various leadership positions in Europe. Venker is a Dutch citizen and holds a Master of Science degree in Applied Physics from the University of Groningen and an Executive MBA degree from the Rotterdam School of Management.Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.51 loss per share (vs kr0.001 profit in 3Q 2023)Third quarter 2024 results: kr0.51 loss per share (down from kr0.001 profit in 3Q 2023). Revenue: kr57.2m (down 10% from 3Q 2023). Net loss: kr13.1m (down kr13.1m from profit in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.공고 • Nov 07+ 4 more updatesMentice AB (publ) to Report Fiscal Year 2024 Final Results on Apr 18, 2025Mentice AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 18, 2025공고 • Oct 22+ 1 more updateMentice AB (Publ) Announces Nomination Committee Appointed for Annual General Meeting 2025Mentice AB (publ) announced that at the Annual General Meeting held on May 23, 2024, it was resolved to adopt instructions and rules of procedure for the Nomination Committee, according to which the Nomination Committee shall consist of the Chairman of the Board and three members representing the three larger shareholders in terms of voting rights as of September 30. The following persons have been appointed to Mentice's Nomination Committee for the Annual General Meeting 2025 Lawrence D Howell, appointed by Karin Howell, Sophie Hagstromer, appointed by Bure Equity; Thomas Ehlin, appointed by Fjarde AP-Fonden; Magnus Nilsson, Chairman of the Board from December 30, 2022; Magnus Nilsson, convener of the first meeting of the Nomination Committee. The Nomination Committee represents approximately 63% of the total number of outstanding shares and votes.New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (€74.3m market cap, or US$80.6m).Reported Earnings • Jul 24Second quarter 2024 earnings released: EPS: kr0.67 (vs kr0.064 in 2Q 2023)Second quarter 2024 results: EPS: kr0.67 (up from kr0.064 in 2Q 2023). Revenue: kr101.7m (up 37% from 2Q 2023). Net income: kr17.2m (up kr15.7m from 2Q 2023). Profit margin: 17% (up from 2.1% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 29Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)Full year 2023 results: kr0.11 loss per share (improved from kr1.22 loss in FY 2022). Revenue: kr275.1m (up 25% from FY 2022). Net loss: kr2.82m (loss narrowed 91% from FY 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.공고 • Apr 26Mentice AB (publ) to Report Fiscal Year 2023 Final Results on Apr 24, 2024Mentice AB (publ) announced that they will report fiscal year 2023 final results on Apr 24, 2024Reported Earnings • Feb 16Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)Full year 2023 results: kr0.11 loss per share (improved from kr1.22 loss in FY 2022). Revenue: kr275.1m (up 25% from FY 2022). Net loss: kr2.82m (loss narrowed 91% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.New Risk • Feb 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.3m (US$99.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€92.3m market cap, or US$99.3m).New Risk • Jan 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.공고 • Jan 06Mentice Receives FDA 510(K) Clearance for AnkyrasMentice announced that the clinical decision support application ANKYRAS has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The approval of product by the FDA demonstrates the safety and effectiveness of Ankyras and confirms commitment to providing innovative and high-quality healthcare solutions. The software is designed to assist interventional neuroradiologists in selecting the most suitable flow diverter before interventional treatment of intracranial aneurysms. Ankyras offers an intuitive and precise solution for clinical treatment planning, leading to more accurate prediction than traditional methods. In the United States, it is estimated that 6.7 million individuals have an unruptured brain aneurysm, meaning that 1 out of every 50 people may be affected. Shockingly, every year, approximately 30,000 people experience a rupture in their brain aneurysm. Unfortunately, this rupture is fatal in nearly 50% of cases. Of those who survive, about 66% suffer some permanent neurological deficit. Ankyras is a platform that provides users with various functionalities to investigate device and treatment options in greater detail. It offers unique morphological assessment metrics that provide customers with a comprehensive and interactive analysis of all artery segments, ensuring they are better equipped to handle real-life challenges. The platform has technology supported by a strong IP portfolio that enables users to evaluate final device length, local expansion and porosity, and precisely align the centerline to create accurate simulations for specific devices. Moving forward, Mentice plans to continue improving the Ankyras solution by incorporating advanced functionalities and more treatment modalities, as well as integrating it with other Mentice solutions, especially the recently acquired Biomodex line of biorealistic haptic simulators. To stay up-to-date with the latest Ankyras advancements and its role in device development and treatment strategies for Intracranial Aneurysm Foundation.공고 • Dec 13Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million.Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million on December 11, 2023.Recent Insider Transactions • Dec 06Director recently bought €71k worth of stockOn the 1st of December, Lawrence Howell bought around 20k shares on-market at roughly €3.53 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €2.0m. Insiders have collectively bought €2.0m more in shares than they have sold in the last 12 months.공고 • Nov 23Mentice (publ) Appoints Ulrika Drotz Voksepp as New Chief Financial Officer, Effective January 2, 2024Mentice AB (publ) appointed Ulrika Drotz Voksepp as CFO, effective January 2, 2024. Ulrikas has previously held several positions where she has demonstrated her ability to establish operational and financial structures to support the business needs of a growing operation. Notably, Ulrika has held Chief Financial Officer positions with Maurten a food tech enterprise; Egain Group a provider of SaaS solutions for energy optimization; Smarteye- a company that specializes in eye- tracking for the automotive industry; and KVD Kvarndammen an e-commerce marketplace for vehicle transactions as both CFO and CEO. During the transition period, Mentice's interim CFO, Henrik Hang, will assist and support Ulrika, who will formally take over the role of CFO on January 2nd. Henrik will continue to support the company's financial activities during the month of January before officially leaving the company on January 31st. The transition period is crucial to ensure a smooth transition and maintain operational andfinancial stability.공고 • Oct 31Mentice AB (Publ) Announces Board AppointmentsMentice AB (publ) announced the following persons have been appointed to the company's nomination committee for the Annual General Meeting 2024: Lawrence D Howell, appointed by Karin Howell, Sophie Hagstromer, appointed by Bure Equity; Thomas Ehlin, appointed by Fjarde AP-Fonden; Magnus Nilsson, Chairman of the Board from December 30, 2022; Magnus Nilsson, convener of the first meeting of the Nomination Committee.Reported Earnings • Oct 30Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr63.3m (up 19% from 3Q 2022). Net income: kr16.0k (up kr7.76m from 3Q 2022). Profit margin: 0% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.공고 • Oct 28Mentice AB (publ), Annual General Meeting, May 23, 2024Mentice AB (publ), Annual General Meeting, May 23, 2024.공고 • Oct 27+ 2 more updatesMentice AB (publ) to Report First Half, 2024 Results on Jul 23, 2024Mentice AB (publ) announced that they will report first half, 2024 results on Jul 23, 2024공고 • Sep 09Mentice AB (Publ) Appoints of Jonatan Sjöström to Its Executive Management Group as Chief Operating Officer, Effective from September 14, 2023Mentice AB (publ) announced the appointment of Jonatan Sjöström to its Executive Management Group as Chief Operating Officer (COO). As part of this new role, Jonatan will assume responsibility for overseeing the company's operational functions, including technology, production, procurement, and information technology, to ensure that Mentice maintains its ambition to deliver exceptional solutions to its global clientele while optimizing digital processes. Jonatan has a wealth of experience in business development, strategy, and technology implementation, having previously served as Head of Strategy and a management team member at Volvo Group Connected Solutions. Additionally, as a seasoned management consultant, he has worked on numerous high-profile projects for several organizations in various sectors, such as automotive, retail, energy, and consumer goods. Jonatan will formally join Mentice on September 14, 2023.New Risk • Aug 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €86.7m (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (€86.7m market cap, or US$94.9m).공고 • Jul 22Mentice AB (publ) Announces Chief Financial Officer ChangesMentice AB (publ) appointed Henrik Hang as interim CFO, effective July 21, 2023. He will succeed Gunilla Andersson, whose departure was announced in May, and has held the position since September 2021. Gunilla will support Henrik during the handover period to ensure a sufficient transition and officially leave the company August 22, 2023.Reported Earnings • Jul 20Second quarter 2023 earnings released: EPS: kr0.06 (vs kr0.72 loss in 2Q 2022)Second quarter 2023 results: EPS: kr0.06 (up from kr0.72 loss in 2Q 2022). Revenue: kr76.9m (up 60% from 2Q 2022). Net income: kr1.47m (up kr19.1m from 2Q 2022). Profit margin: 1.9% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 18% per year.Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Chairman of the Board Magnus Nilsson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • May 30Mentice AB (publ) Announces Resignation of Gunilla Andersson as Chief Financial OfficerMentice AB (publ) announced that its CFO, Gunilla Andersson, has decided to leave Mentice. Gunilla will formally leave the Company at the end of August 2023 and be replaced by an interim CFO until a new CFO has been appointed.Reported Earnings • Apr 09Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)Full year 2022 results: kr1.22 loss per share (further deteriorated from kr1.18 loss in FY 2021). Revenue: kr219.4m (up 19% from FY 2021). Net loss: kr30.7m (loss widened 5.0% from FY 2021). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Reported Earnings • Feb 05Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)Full year 2022 results: kr1.22 loss per share (further deteriorated from kr1.18 loss in FY 2021). Revenue: kr218.0m (up 18% from FY 2021). Net loss: kr30.7m (loss widened 5.0% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 20% per year.Reported Earnings • Oct 30Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.29 loss in 3Q 2021)Third quarter 2022 results: kr0.30 loss per share (further deteriorated from kr0.29 loss in 3Q 2021). Revenue: kr51.1m (up 32% from 3Q 2021). Net loss: kr7.75m (loss widened 7.1% from 3Q 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.공고 • Oct 27+ 2 more updatesMentice AB (publ) to Report First Half, 2023 Results on Jul 20, 2023Mentice AB (publ) announced that they will report first half, 2023 results on Jul 20, 2023공고 • Oct 01+ 1 more updateMentice AB (publ), Annual General Meeting, May 11, 2023Mentice AB (publ), Annual General Meeting, May 11, 2023. Agenda: To approve election of a Chairman of the meeting; to discuss the decision of the number of Board members; to discuss decision on remuneration to the Board members and to the Auditor; to consider election of Board members and Chairman of the Board; and to discuss principles for appointing Nomination Committee.Reported Earnings • Jul 22Second quarter 2022 earnings released: kr0.71 loss per share (vs kr0.22 loss in 2Q 2021)Second quarter 2022 results: kr0.71 loss per share (down from kr0.22 loss in 2Q 2021). Revenue: kr45.1m (down 2.7% from 2Q 2021). Net loss: kr17.6m (loss widened 229% from 2Q 2021). Over the next year, revenue is forecast to grow 41%, compared to a 16% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.공고 • Jul 21Mentice AB (publ) to Report Q4, 2022 Results on Feb 09, 2023Mentice AB (publ) announced that they will report Q4, 2022 results on Feb 09, 2023공고 • Jul 02Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL.Mentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million on June 9, 2022. Consideration amount of €1.80 million with a possible additional purchase amount of €0.975 million, and with a total purchase consideration amounting to approximately €2.775 million to be paid in cash. The completion of the Acquisition is expected to occur in June 2022 and is conditioned upon customary terms and completed external financing. The agreement and the completion of the said agreement is conditioned upon Mentice financing the transaction, which is planned to be performed through a directed new share issue. Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL on June 30, 2022.공고 • Jun 10+ 1 more updateMentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million.Mentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million on June 9, 2022. Consideration amount of €1.80 million with a possible additional purchase amount of €0.975 million, and with a total purchase consideration amounting to approximately €2.775 million to be paid in cash. The completion of the Acquisition is expected to occur in June 2022 and is conditioned upon customary terms and completed external financing. The agreement and the completion of the said agreement is conditioned upon Mentice financing the transaction, which is planned to be performed through a directed new share issue.Reported Earnings • Apr 29First quarter 2022 earnings released: kr0.30 loss per share (vs kr0.50 loss in 1Q 2021)First quarter 2022 results: kr0.30 loss per share (up from kr0.50 loss in 1Q 2021). Revenue: kr54.7m (up 69% from 1Q 2021). Net loss: kr7.43m (loss narrowed 40% from 1Q 2021). Over the next year, revenue is forecast to grow 27%, compared to a 26% growth forecast for the industry in Germany.Board Change • Apr 29High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Magnus Nilsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공고 • Apr 28Mentice AB (publ) Announces Change of Chairman of Board, Effective December 30, 2022Mentice AB (publ) at its annual general meeting held on April 27, 2022, announced that Lawrence D. Howell was re-elected as chairman of the board up and until December 30, 2022 and Magnus Nilsson was elected as chairman of the board from December 30, 2022 up and until the annual general meeting of 2023.Board Change • Apr 07High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Magnus Nilsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공고 • Feb 15Mentice Appoints Jan Grund Pedersen as New Vice President of Strategic Alliances & Business DevelopmentMentice announced the appointment of Jan Grund Pedersen as the Vice President for Strategic Alliances & Business Development. Jan possesses over twenty-five years of extensive experience within Virtual Reality (VR) simulation and is one of the founding members of Mentice. Throughout Jan's career, he has spearheaded many innovative areas that have changed the way Physicians see Medical simulation.공고 • Feb 12Mentice AB (publ) to Report Fiscal Year 2021 Results on Apr 06, 2022Mentice AB (publ) announced that they will report fiscal year 2021 results on Apr 06, 2022Reported Earnings • Feb 04Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr1.18 loss per share (down from kr0.54 loss in FY 2020). Revenue: kr190.2m (up 38% from FY 2020). Net loss: kr29.2m (loss widened 123% from FY 2020). Revenue exceeded analyst estimates by 2.9%. Over the next year, revenue is forecast to grow 42%, compared to a 48% growth forecast for the industry in Germany.Reported Earnings • Oct 29Third quarter 2021 earnings released: kr0.29 loss per share (vs kr0.014 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr39.7m (up 19% from 3Q 2020). Net loss: kr7.23m (loss widened kr6.89m from 3Q 2020).Board Change • Sep 14Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 09Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 07Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Executive Departure • Sep 07Chief Financial Officer Elisabet Lund has left the companyOn the 1st of September, Elisabet Lund's tenure as Chief Financial Officer ended. As of June 2021, Elisabet still personally held only 5.00k shares (€41k worth at the time). Elisabet is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 5.17 years.Reported Earnings • Jul 27Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: kr46.4m (up 91% from 2Q 2020). Net loss: kr5.36m (loss narrowed 52% from 2Q 2020).Board Change • Jul 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 23Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: kr46.4m (up 91% from 2Q 2020). Net loss: kr5.36m (loss narrowed 52% from 2Q 2020).Reported Earnings • May 01First quarter 2021 earnings released: kr0.50 loss per share (vs kr0.21 loss in 1Q 2020)The company reported a poor first quarter result with increased losses and weaker control over costs, although revenues were flat. First quarter 2021 results: Revenue: kr33.5m (flat on 1Q 2020). Net loss: kr12.4m (loss widened 149% from 1Q 2020).Is New 90 Day High Low • Feb 06New 90-day low: €7.52The company is down 3.0% from its price of €7.77 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.74 per share.Reported Earnings • Feb 06Full year 2020 earnings released: kr0.54 loss per share (vs kr1.05 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr150.9m (up 1.0% from FY 2019). Net loss: kr13.1m (loss narrowed 36% from FY 2019).Analyst Estimate Surprise Post Earnings • Feb 06Revenue misses expectationsRevenue missed analyst estimates by 14%. Over the next year, revenue is forecast to grow 33%, compared to a 19% growth forecast for the Healthcare Services industry in Germany.공고 • Jan 14Mentice Announces Executive AppointmentsMentice appointed Martin Harris as Global Vice President of Marketing. Mr. Harris has many years' experience with Mentice and was previously responsible for Strategic Alliance partnerships, which he will continue to manage as part of Marketing. The new marketing organization will also assume responsibility for Sales Operations and Sales Training to support the continued regional expansion of the Mentice sales force. Kjell Asserlind has been appointed as Vice President and General Manager for the EMEA region. Mr. Asserlind previously held the position of Global VP for Healthcare Systems Sales. Thanos Karras, appointed General Manager for the Americas region in July 2020 will continue in this role with an expanded organization and additional responsibility. For the APAC region, Mentice has externally recruited a Vice President and General Manager to be separately announced. In addition, Ben Speich has been appointed to run the Vascular Simulations business, acquired in October 2020. Mr. Speich will serve as General Manager for this business unit and be responsible for its operations. He was previously responsible for Global Support at Mentice.공고 • Nov 14+ 3 more updatesMentice AB (publ) to Report Fiscal Year 2020 Results on Feb 04, 2021Mentice AB (publ) announced that they will report fiscal year 2020 results at 8:30 AM, Central Europe Standard Time on Feb 04, 2021Reported Earnings • Nov 13Third quarter 2020 earnings released: kr0.01 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr35.8m (up 22% from 3Q 2019). Net loss: kr340.0k (loss narrowed 96% from 3Q 2019).Analyst Estimate Surprise Post Earnings • Nov 13Revenue misses expectationsRevenue missed analyst estimates by 1.8%. Over the next year, revenue is forecast to grow 28%, compared to a 242% growth forecast for the Healthcare Services industry in Germany.공고 • Nov 07+ 1 more updateMentice AB (Publ) Announces Nomination CommitteeMentice AB (publ) announced that the nomination committee for the company's Annual General Meeting 2021 has been appointed. The following members have been appointed to Mentice nomination committee for the 2021 Annual General Meeting: Karin Howell as largest shareholder; Sophie Hagströmer, representing Bure Equity; Emma Viotti, representing Handelsbanken Fonder; Lawrence D Howell, Chairman of the Board.Is New 90 Day High Low • Oct 29New 90-day low: €7.00The company is down 1.0% from its price of €7.10 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare Services industry, which is up 2.0% over the same period.공고 • Oct 10Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million.Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million on October 8, 2020. The purchase price amounts to $0.18 million with a possible additional purchase price of maximum $0.07 million. Payment will be made in cash of about $0.09 million and remaining $0.09 million through by an off-set issuance of new shares in Mentice corresponding to the agreed purchase price which will be issued based on the authorization for the board to resolve on new issuance of shares given at the annual shareholders’ meeting on May 27 2020. Purchase price will be paid with a directed new shares issue in MenticeAB and cash payment. Mentice intends to initially add the myIRlog™ services to its Mentice Live™ cloud offering and over time to roll out corresponding logbook services to all specialties within the endovascular and interventional fields. The transaction is subject to customary closing conditions and completion of the acquisition is expected to take place in the beginning of October 2020.공고 • Oct 02Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million.Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million on October 1, 2020. Under the terms of agreement, payment will be made through by an off-set issuance of new shares in Mentice corresponding to the agreed purchase price of $5.6 million and with a possible additional purchase price of maximum $0.4 million. Shares which will be issued based on the authorization for the Board to resolve on new issuance of shares given at the annual shareholders’ meeting on May 27, 2020. The transaction includes all the Vascular Simulations assets and significant staff where initially Vascular Simulations will be run as a separate business unit during the integration in the rest of the Mentice enterprise. Vascular Simulation had $2.2 million in revenue for the year ending December 31, 2019 and for the first 9 months 2020, Vascular Simulation had $1 million in revenue. The transaction is subject to customary closing conditions and is expected to close in the beginning of October 2020.공고 • Aug 16Mentice AB (publ) to Report Q2, 2020 Results on Aug 13, 2020Mentice AB (publ) announced that they will report Q2, 2020 results at 9:30 AM, Central European Standard Time on Aug 13, 2020공고 • Aug 14Mentice AB (publ) to Report Q3, 2020 Results on Nov 12, 2020Mentice AB (publ) announced that they will report Q3, 2020 results at 8:30 AM, Central European Standard Time on Nov 12, 2020이익 및 매출 성장 예측DB:MN2 - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028382202848212/31/202735171736212/31/2026318-9425726/30/2026303-51225N/A3/31/2026287-21-59N/A12/31/2025279-32-36-20N/A9/30/2025274-43-22-8N/A6/30/2025262-56-170N/A3/31/2025299-21-413N/A12/31/2024290-18118N/A9/30/2024276-23-20-4N/A6/30/2024282-103141N/A3/31/2024255-262837N/A12/31/2023275-33037N/A9/30/202327326171N/A6/30/2023261-61324N/A3/31/2023230-25-75N/A12/31/2022219-31215N/A9/30/2022215-37-16-4N/A6/30/2022205-36-23-7N/A3/31/2022207-24-219N/A12/31/2021185-29-31-5N/A9/30/2021165-22-208N/A6/30/2021158-15-199N/A3/31/2021136-21-1016N/A12/31/2020138-13531N/A9/30/2020152-9-21-6N/A6/30/2020148-17-29-16N/A3/31/2020156-17N/A-32N/A12/31/2019149-21N/A-37N/A9/30/2019154-1N/A-8N/A6/30/20191618N/A11N/A3/31/201915614N/A9N/A12/31/201815720N/A16N/A12/31/20171096N/A16N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MN2 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.1%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: MN2 (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: MN2 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: MN2 의 수익(연간 9.3%)이 German 시장(연간 6.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: MN2 의 수익(연간 9.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MN2의 자본 수익률은 3년 후 9.1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/13 23:38종가2026/08/13 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Mentice AB (publ)는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Maria Karlsson OsipovaDNB Carnegie Commissioned ResearchRikard EngbergDNB Carnegie Commissioned ResearchChristian LeePareto Securities
New Risk • Jul 26New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€38.1m market cap, or US$43.3m).
Reported Earnings • Jul 24Second quarter 2026 earnings released: kr0.03 loss per share (vs kr0.57 loss in 2Q 2025)Second quarter 2026 results: kr0.03 loss per share (improved from kr0.57 loss in 2Q 2025). Revenue: kr83.0m (up 31% from 2Q 2025). Net loss: kr880.0k (loss narrowed 95% from 2Q 2025). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings.
공고 • Jul 23+ 1 more updateMentice AB (publ) to Report Fiscal Year 2026 Results on Apr 22, 2027Mentice AB (publ) announced that they will report fiscal year 2026 results on Apr 22, 2027
공고 • Feb 27Mentice AB (publ) Announces Board ChangesMentice AB (publ) at its EGM held on February 26, 2026, announced that Göran Malmberg, previously CEO of the Company, was elected, for the period until the next annual shareholders’ meeting, as a new board member in the Company. Former board members David J. Ballard, Eola Änggård Runsten and Magnus Nilsson stepped down from the board. Göran Malmberg served as a board member in 2007 before assuming the role of CEO in January 2008, a position he held until December 31, 2024, when Frans Venker assumed the role as new CEO. Since 2025, Göran Malmberg serves as an advisor to the Company and its owners, and following the recent change of ownership, he now in addition assumes the role of board member.
공고 • Feb 12Mentice AB (publ) to Report Fiscal Year 2025 Final Results on Apr 23, 2026Mentice AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 23, 2026
공고 • Feb 05+ 3 more updatesMentice AB (publ) to Report Q1, 2026 Results on May 07, 2026Mentice AB (publ) announced that they will report Q1, 2026 results on May 07, 2026
공고 • Oct 24Mentice AB (publ), Annual General Meeting, May 26, 2026Mentice AB (publ), Annual General Meeting, May 26, 2026. Location: gothenburg Sweden
공고 • Jul 24Mentice AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 31.961063 million.Mentice AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 31.961063 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,556,885 Price\Range: SEK 12.5 Transaction Features: Rights Offering
공고 • Jul 11Mentice AB (publ) Announces Consolidation of Physical Simulation Operations to Strengthen Long-Term Efficiency and Global Service DeliveryMentice AB (publ) announced the decision to consolidate its research and development (R&D) and manufacturing operations for its entire physical simulation portfolio to its new facility in Denver, Colorado, USA.
공고 • Nov 29Mentice AB (publ) Announces the Appointment of Frans Venker as New Chief Executive Officer, Effective January 1, 2025Mentice AB (publ) announced the appointment of Frans Venker as its new Chief Executive Officer, effective January 1, 2025. Frans Venker succeeds Göran Malmberg, who has served the company for 17 years and will remain in an advisory role. Göran Malmberg’s retirement as CEO was previously announced in May 2024. With over 25 years of experience in the industry addressing the same or related medical needs and therapies as Mentice, Venker brings a wealth of expertise and a proven track record in driving innovation, operational excellence, and sustainable growth. Most recently, he led the Business Unit for Computed Tomography and Advanced Molecular Imaging at Philips based in the USA. Before this role, he was the Business Leader of image-guided Therapy for Philips North America and a member of the Philips North America Leadership Team and has served as Global Marketing Leader for Diagnostic X-Ray in Shanghai, China, in addition to various leadership positions in Europe. Venker is a Dutch citizen and holds a Master of Science degree in Applied Physics from the University of Groningen and an Executive MBA degree from the Rotterdam School of Management.
Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.51 loss per share (vs kr0.001 profit in 3Q 2023)Third quarter 2024 results: kr0.51 loss per share (down from kr0.001 profit in 3Q 2023). Revenue: kr57.2m (down 10% from 3Q 2023). Net loss: kr13.1m (down kr13.1m from profit in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
공고 • Nov 07+ 4 more updatesMentice AB (publ) to Report Fiscal Year 2024 Final Results on Apr 18, 2025Mentice AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 18, 2025
공고 • Oct 22+ 1 more updateMentice AB (Publ) Announces Nomination Committee Appointed for Annual General Meeting 2025Mentice AB (publ) announced that at the Annual General Meeting held on May 23, 2024, it was resolved to adopt instructions and rules of procedure for the Nomination Committee, according to which the Nomination Committee shall consist of the Chairman of the Board and three members representing the three larger shareholders in terms of voting rights as of September 30. The following persons have been appointed to Mentice's Nomination Committee for the Annual General Meeting 2025 Lawrence D Howell, appointed by Karin Howell, Sophie Hagstromer, appointed by Bure Equity; Thomas Ehlin, appointed by Fjarde AP-Fonden; Magnus Nilsson, Chairman of the Board from December 30, 2022; Magnus Nilsson, convener of the first meeting of the Nomination Committee. The Nomination Committee represents approximately 63% of the total number of outstanding shares and votes.
New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (€74.3m market cap, or US$80.6m).
Reported Earnings • Jul 24Second quarter 2024 earnings released: EPS: kr0.67 (vs kr0.064 in 2Q 2023)Second quarter 2024 results: EPS: kr0.67 (up from kr0.064 in 2Q 2023). Revenue: kr101.7m (up 37% from 2Q 2023). Net income: kr17.2m (up kr15.7m from 2Q 2023). Profit margin: 17% (up from 2.1% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 29Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)Full year 2023 results: kr0.11 loss per share (improved from kr1.22 loss in FY 2022). Revenue: kr275.1m (up 25% from FY 2022). Net loss: kr2.82m (loss narrowed 91% from FY 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
공고 • Apr 26Mentice AB (publ) to Report Fiscal Year 2023 Final Results on Apr 24, 2024Mentice AB (publ) announced that they will report fiscal year 2023 final results on Apr 24, 2024
Reported Earnings • Feb 16Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)Full year 2023 results: kr0.11 loss per share (improved from kr1.22 loss in FY 2022). Revenue: kr275.1m (up 25% from FY 2022). Net loss: kr2.82m (loss narrowed 91% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
New Risk • Feb 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.3m (US$99.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€92.3m market cap, or US$99.3m).
New Risk • Jan 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
공고 • Jan 06Mentice Receives FDA 510(K) Clearance for AnkyrasMentice announced that the clinical decision support application ANKYRAS has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The approval of product by the FDA demonstrates the safety and effectiveness of Ankyras and confirms commitment to providing innovative and high-quality healthcare solutions. The software is designed to assist interventional neuroradiologists in selecting the most suitable flow diverter before interventional treatment of intracranial aneurysms. Ankyras offers an intuitive and precise solution for clinical treatment planning, leading to more accurate prediction than traditional methods. In the United States, it is estimated that 6.7 million individuals have an unruptured brain aneurysm, meaning that 1 out of every 50 people may be affected. Shockingly, every year, approximately 30,000 people experience a rupture in their brain aneurysm. Unfortunately, this rupture is fatal in nearly 50% of cases. Of those who survive, about 66% suffer some permanent neurological deficit. Ankyras is a platform that provides users with various functionalities to investigate device and treatment options in greater detail. It offers unique morphological assessment metrics that provide customers with a comprehensive and interactive analysis of all artery segments, ensuring they are better equipped to handle real-life challenges. The platform has technology supported by a strong IP portfolio that enables users to evaluate final device length, local expansion and porosity, and precisely align the centerline to create accurate simulations for specific devices. Moving forward, Mentice plans to continue improving the Ankyras solution by incorporating advanced functionalities and more treatment modalities, as well as integrating it with other Mentice solutions, especially the recently acquired Biomodex line of biorealistic haptic simulators. To stay up-to-date with the latest Ankyras advancements and its role in device development and treatment strategies for Intracranial Aneurysm Foundation.
공고 • Dec 13Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million.Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million on December 11, 2023.
Recent Insider Transactions • Dec 06Director recently bought €71k worth of stockOn the 1st of December, Lawrence Howell bought around 20k shares on-market at roughly €3.53 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €2.0m. Insiders have collectively bought €2.0m more in shares than they have sold in the last 12 months.
공고 • Nov 23Mentice (publ) Appoints Ulrika Drotz Voksepp as New Chief Financial Officer, Effective January 2, 2024Mentice AB (publ) appointed Ulrika Drotz Voksepp as CFO, effective January 2, 2024. Ulrikas has previously held several positions where she has demonstrated her ability to establish operational and financial structures to support the business needs of a growing operation. Notably, Ulrika has held Chief Financial Officer positions with Maurten a food tech enterprise; Egain Group a provider of SaaS solutions for energy optimization; Smarteye- a company that specializes in eye- tracking for the automotive industry; and KVD Kvarndammen an e-commerce marketplace for vehicle transactions as both CFO and CEO. During the transition period, Mentice's interim CFO, Henrik Hang, will assist and support Ulrika, who will formally take over the role of CFO on January 2nd. Henrik will continue to support the company's financial activities during the month of January before officially leaving the company on January 31st. The transition period is crucial to ensure a smooth transition and maintain operational andfinancial stability.
공고 • Oct 31Mentice AB (Publ) Announces Board AppointmentsMentice AB (publ) announced the following persons have been appointed to the company's nomination committee for the Annual General Meeting 2024: Lawrence D Howell, appointed by Karin Howell, Sophie Hagstromer, appointed by Bure Equity; Thomas Ehlin, appointed by Fjarde AP-Fonden; Magnus Nilsson, Chairman of the Board from December 30, 2022; Magnus Nilsson, convener of the first meeting of the Nomination Committee.
Reported Earnings • Oct 30Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr63.3m (up 19% from 3Q 2022). Net income: kr16.0k (up kr7.76m from 3Q 2022). Profit margin: 0% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
공고 • Oct 28Mentice AB (publ), Annual General Meeting, May 23, 2024Mentice AB (publ), Annual General Meeting, May 23, 2024.
공고 • Oct 27+ 2 more updatesMentice AB (publ) to Report First Half, 2024 Results on Jul 23, 2024Mentice AB (publ) announced that they will report first half, 2024 results on Jul 23, 2024
공고 • Sep 09Mentice AB (Publ) Appoints of Jonatan Sjöström to Its Executive Management Group as Chief Operating Officer, Effective from September 14, 2023Mentice AB (publ) announced the appointment of Jonatan Sjöström to its Executive Management Group as Chief Operating Officer (COO). As part of this new role, Jonatan will assume responsibility for overseeing the company's operational functions, including technology, production, procurement, and information technology, to ensure that Mentice maintains its ambition to deliver exceptional solutions to its global clientele while optimizing digital processes. Jonatan has a wealth of experience in business development, strategy, and technology implementation, having previously served as Head of Strategy and a management team member at Volvo Group Connected Solutions. Additionally, as a seasoned management consultant, he has worked on numerous high-profile projects for several organizations in various sectors, such as automotive, retail, energy, and consumer goods. Jonatan will formally join Mentice on September 14, 2023.
New Risk • Aug 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €86.7m (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (€86.7m market cap, or US$94.9m).
공고 • Jul 22Mentice AB (publ) Announces Chief Financial Officer ChangesMentice AB (publ) appointed Henrik Hang as interim CFO, effective July 21, 2023. He will succeed Gunilla Andersson, whose departure was announced in May, and has held the position since September 2021. Gunilla will support Henrik during the handover period to ensure a sufficient transition and officially leave the company August 22, 2023.
Reported Earnings • Jul 20Second quarter 2023 earnings released: EPS: kr0.06 (vs kr0.72 loss in 2Q 2022)Second quarter 2023 results: EPS: kr0.06 (up from kr0.72 loss in 2Q 2022). Revenue: kr76.9m (up 60% from 2Q 2022). Net income: kr1.47m (up kr19.1m from 2Q 2022). Profit margin: 1.9% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 18% per year.
Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Chairman of the Board Magnus Nilsson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • May 30Mentice AB (publ) Announces Resignation of Gunilla Andersson as Chief Financial OfficerMentice AB (publ) announced that its CFO, Gunilla Andersson, has decided to leave Mentice. Gunilla will formally leave the Company at the end of August 2023 and be replaced by an interim CFO until a new CFO has been appointed.
Reported Earnings • Apr 09Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)Full year 2022 results: kr1.22 loss per share (further deteriorated from kr1.18 loss in FY 2021). Revenue: kr219.4m (up 19% from FY 2021). Net loss: kr30.7m (loss widened 5.0% from FY 2021). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Reported Earnings • Feb 05Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)Full year 2022 results: kr1.22 loss per share (further deteriorated from kr1.18 loss in FY 2021). Revenue: kr218.0m (up 18% from FY 2021). Net loss: kr30.7m (loss widened 5.0% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 20% per year.
Reported Earnings • Oct 30Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.29 loss in 3Q 2021)Third quarter 2022 results: kr0.30 loss per share (further deteriorated from kr0.29 loss in 3Q 2021). Revenue: kr51.1m (up 32% from 3Q 2021). Net loss: kr7.75m (loss widened 7.1% from 3Q 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.
공고 • Oct 27+ 2 more updatesMentice AB (publ) to Report First Half, 2023 Results on Jul 20, 2023Mentice AB (publ) announced that they will report first half, 2023 results on Jul 20, 2023
공고 • Oct 01+ 1 more updateMentice AB (publ), Annual General Meeting, May 11, 2023Mentice AB (publ), Annual General Meeting, May 11, 2023. Agenda: To approve election of a Chairman of the meeting; to discuss the decision of the number of Board members; to discuss decision on remuneration to the Board members and to the Auditor; to consider election of Board members and Chairman of the Board; and to discuss principles for appointing Nomination Committee.
Reported Earnings • Jul 22Second quarter 2022 earnings released: kr0.71 loss per share (vs kr0.22 loss in 2Q 2021)Second quarter 2022 results: kr0.71 loss per share (down from kr0.22 loss in 2Q 2021). Revenue: kr45.1m (down 2.7% from 2Q 2021). Net loss: kr17.6m (loss widened 229% from 2Q 2021). Over the next year, revenue is forecast to grow 41%, compared to a 16% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
공고 • Jul 21Mentice AB (publ) to Report Q4, 2022 Results on Feb 09, 2023Mentice AB (publ) announced that they will report Q4, 2022 results on Feb 09, 2023
공고 • Jul 02Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL.Mentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million on June 9, 2022. Consideration amount of €1.80 million with a possible additional purchase amount of €0.975 million, and with a total purchase consideration amounting to approximately €2.775 million to be paid in cash. The completion of the Acquisition is expected to occur in June 2022 and is conditioned upon customary terms and completed external financing. The agreement and the completion of the said agreement is conditioned upon Mentice financing the transaction, which is planned to be performed through a directed new share issue. Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL on June 30, 2022.
공고 • Jun 10+ 1 more updateMentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million.Mentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million on June 9, 2022. Consideration amount of €1.80 million with a possible additional purchase amount of €0.975 million, and with a total purchase consideration amounting to approximately €2.775 million to be paid in cash. The completion of the Acquisition is expected to occur in June 2022 and is conditioned upon customary terms and completed external financing. The agreement and the completion of the said agreement is conditioned upon Mentice financing the transaction, which is planned to be performed through a directed new share issue.
Reported Earnings • Apr 29First quarter 2022 earnings released: kr0.30 loss per share (vs kr0.50 loss in 1Q 2021)First quarter 2022 results: kr0.30 loss per share (up from kr0.50 loss in 1Q 2021). Revenue: kr54.7m (up 69% from 1Q 2021). Net loss: kr7.43m (loss narrowed 40% from 1Q 2021). Over the next year, revenue is forecast to grow 27%, compared to a 26% growth forecast for the industry in Germany.
Board Change • Apr 29High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Magnus Nilsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공고 • Apr 28Mentice AB (publ) Announces Change of Chairman of Board, Effective December 30, 2022Mentice AB (publ) at its annual general meeting held on April 27, 2022, announced that Lawrence D. Howell was re-elected as chairman of the board up and until December 30, 2022 and Magnus Nilsson was elected as chairman of the board from December 30, 2022 up and until the annual general meeting of 2023.
Board Change • Apr 07High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Magnus Nilsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공고 • Feb 15Mentice Appoints Jan Grund Pedersen as New Vice President of Strategic Alliances & Business DevelopmentMentice announced the appointment of Jan Grund Pedersen as the Vice President for Strategic Alliances & Business Development. Jan possesses over twenty-five years of extensive experience within Virtual Reality (VR) simulation and is one of the founding members of Mentice. Throughout Jan's career, he has spearheaded many innovative areas that have changed the way Physicians see Medical simulation.
공고 • Feb 12Mentice AB (publ) to Report Fiscal Year 2021 Results on Apr 06, 2022Mentice AB (publ) announced that they will report fiscal year 2021 results on Apr 06, 2022
Reported Earnings • Feb 04Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr1.18 loss per share (down from kr0.54 loss in FY 2020). Revenue: kr190.2m (up 38% from FY 2020). Net loss: kr29.2m (loss widened 123% from FY 2020). Revenue exceeded analyst estimates by 2.9%. Over the next year, revenue is forecast to grow 42%, compared to a 48% growth forecast for the industry in Germany.
Reported Earnings • Oct 29Third quarter 2021 earnings released: kr0.29 loss per share (vs kr0.014 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr39.7m (up 19% from 3Q 2020). Net loss: kr7.23m (loss widened kr6.89m from 3Q 2020).
Board Change • Sep 14Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 09Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 07Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Executive Departure • Sep 07Chief Financial Officer Elisabet Lund has left the companyOn the 1st of September, Elisabet Lund's tenure as Chief Financial Officer ended. As of June 2021, Elisabet still personally held only 5.00k shares (€41k worth at the time). Elisabet is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 5.17 years.
Reported Earnings • Jul 27Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: kr46.4m (up 91% from 2Q 2020). Net loss: kr5.36m (loss narrowed 52% from 2Q 2020).
Board Change • Jul 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 23Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: kr46.4m (up 91% from 2Q 2020). Net loss: kr5.36m (loss narrowed 52% from 2Q 2020).
Reported Earnings • May 01First quarter 2021 earnings released: kr0.50 loss per share (vs kr0.21 loss in 1Q 2020)The company reported a poor first quarter result with increased losses and weaker control over costs, although revenues were flat. First quarter 2021 results: Revenue: kr33.5m (flat on 1Q 2020). Net loss: kr12.4m (loss widened 149% from 1Q 2020).
Is New 90 Day High Low • Feb 06New 90-day low: €7.52The company is down 3.0% from its price of €7.77 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.74 per share.
Reported Earnings • Feb 06Full year 2020 earnings released: kr0.54 loss per share (vs kr1.05 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr150.9m (up 1.0% from FY 2019). Net loss: kr13.1m (loss narrowed 36% from FY 2019).
Analyst Estimate Surprise Post Earnings • Feb 06Revenue misses expectationsRevenue missed analyst estimates by 14%. Over the next year, revenue is forecast to grow 33%, compared to a 19% growth forecast for the Healthcare Services industry in Germany.
공고 • Jan 14Mentice Announces Executive AppointmentsMentice appointed Martin Harris as Global Vice President of Marketing. Mr. Harris has many years' experience with Mentice and was previously responsible for Strategic Alliance partnerships, which he will continue to manage as part of Marketing. The new marketing organization will also assume responsibility for Sales Operations and Sales Training to support the continued regional expansion of the Mentice sales force. Kjell Asserlind has been appointed as Vice President and General Manager for the EMEA region. Mr. Asserlind previously held the position of Global VP for Healthcare Systems Sales. Thanos Karras, appointed General Manager for the Americas region in July 2020 will continue in this role with an expanded organization and additional responsibility. For the APAC region, Mentice has externally recruited a Vice President and General Manager to be separately announced. In addition, Ben Speich has been appointed to run the Vascular Simulations business, acquired in October 2020. Mr. Speich will serve as General Manager for this business unit and be responsible for its operations. He was previously responsible for Global Support at Mentice.
공고 • Nov 14+ 3 more updatesMentice AB (publ) to Report Fiscal Year 2020 Results on Feb 04, 2021Mentice AB (publ) announced that they will report fiscal year 2020 results at 8:30 AM, Central Europe Standard Time on Feb 04, 2021
Reported Earnings • Nov 13Third quarter 2020 earnings released: kr0.01 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr35.8m (up 22% from 3Q 2019). Net loss: kr340.0k (loss narrowed 96% from 3Q 2019).
Analyst Estimate Surprise Post Earnings • Nov 13Revenue misses expectationsRevenue missed analyst estimates by 1.8%. Over the next year, revenue is forecast to grow 28%, compared to a 242% growth forecast for the Healthcare Services industry in Germany.
공고 • Nov 07+ 1 more updateMentice AB (Publ) Announces Nomination CommitteeMentice AB (publ) announced that the nomination committee for the company's Annual General Meeting 2021 has been appointed. The following members have been appointed to Mentice nomination committee for the 2021 Annual General Meeting: Karin Howell as largest shareholder; Sophie Hagströmer, representing Bure Equity; Emma Viotti, representing Handelsbanken Fonder; Lawrence D Howell, Chairman of the Board.
Is New 90 Day High Low • Oct 29New 90-day low: €7.00The company is down 1.0% from its price of €7.10 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare Services industry, which is up 2.0% over the same period.
공고 • Oct 10Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million.Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million on October 8, 2020. The purchase price amounts to $0.18 million with a possible additional purchase price of maximum $0.07 million. Payment will be made in cash of about $0.09 million and remaining $0.09 million through by an off-set issuance of new shares in Mentice corresponding to the agreed purchase price which will be issued based on the authorization for the board to resolve on new issuance of shares given at the annual shareholders’ meeting on May 27 2020. Purchase price will be paid with a directed new shares issue in MenticeAB and cash payment. Mentice intends to initially add the myIRlog™ services to its Mentice Live™ cloud offering and over time to roll out corresponding logbook services to all specialties within the endovascular and interventional fields. The transaction is subject to customary closing conditions and completion of the acquisition is expected to take place in the beginning of October 2020.
공고 • Oct 02Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million.Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million on October 1, 2020. Under the terms of agreement, payment will be made through by an off-set issuance of new shares in Mentice corresponding to the agreed purchase price of $5.6 million and with a possible additional purchase price of maximum $0.4 million. Shares which will be issued based on the authorization for the Board to resolve on new issuance of shares given at the annual shareholders’ meeting on May 27, 2020. The transaction includes all the Vascular Simulations assets and significant staff where initially Vascular Simulations will be run as a separate business unit during the integration in the rest of the Mentice enterprise. Vascular Simulation had $2.2 million in revenue for the year ending December 31, 2019 and for the first 9 months 2020, Vascular Simulation had $1 million in revenue. The transaction is subject to customary closing conditions and is expected to close in the beginning of October 2020.
공고 • Aug 16Mentice AB (publ) to Report Q2, 2020 Results on Aug 13, 2020Mentice AB (publ) announced that they will report Q2, 2020 results at 9:30 AM, Central European Standard Time on Aug 13, 2020
공고 • Aug 14Mentice AB (publ) to Report Q3, 2020 Results on Nov 12, 2020Mentice AB (publ) announced that they will report Q3, 2020 results at 8:30 AM, Central European Standard Time on Nov 12, 2020